<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Ninlaro II-25 EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.5pt;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:18.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Char\,Char Char\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	mso-style-link:"Comment Text Char\,Char Char Char\,Char Char1\,Comment Text Char Char Char Char\,Comment Text Char1 Char Char\,Comment Text Char1 Char1";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Char Char Char\,Char Char1\,Comment Text Char Char Char Char\,Comment Text Char1 Char Char\,Comment Text Char1 Char1";
	mso-style-link:"Comment Text\,Char\,Char Char\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"MS Gothic";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Cambria",serif;
	font-weight:bold;
	font-style:italic;}
span.A13
	{mso-style-name:A13;
	font-family:"TimesNewRomanPS",serif;
	color:#221E1F;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
p.CCDSMinorHeading1, li.CCDSMinorHeading1, div.CCDSMinorHeading1
	{mso-style-name:"CCDS Minor Heading 1";
	mso-style-link:"CCDS Minor Heading 1 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:18.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.CCDSMinorHeading1Char
	{mso-style-name:"CCDS Minor Heading 1 Char";
	mso-style-link:"CCDS Minor Heading 1";
	font-family:"MS Gothic";
	font-weight:bold;}
p.CCDSMinorSubheading1, li.CCDSMinorSubheading1, div.CCDSMinorSubheading1
	{mso-style-name:"CCDS Minor Subheading 1";
	mso-style-link:"CCDS Minor Subheading 1 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:18.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.CCDSMinorSubheading2, li.CCDSMinorSubheading2, div.CCDSMinorSubheading2
	{mso-style-name:"CCDS Minor Subheading 2";
	mso-style-link:"CCDS Minor Subheading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:18.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	text-decoration:underline;}
span.CCDSMinorSubheading1Char
	{mso-style-name:"CCDS Minor Subheading 1 Char";
	mso-style-link:"CCDS Minor Subheading 1";
	font-family:"MS Gothic";
	font-weight:bold;
	font-style:italic;}
span.CCDSMinorSubheading2Char
	{mso-style-name:"CCDS Minor Subheading 2 Char";
	mso-style-link:"CCDS Minor Subheading 2";
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	text-decoration:underline;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.CM36, li.CM36, div.CM36
	{mso-style-name:CM36;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"LZLLQG+TimesNewRoman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.KommentartextZchn1
	{mso-style-name:"Kommentartext Zchn1";}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.readonlyfield1
	{mso-style-name:readonlyfield1;
	color:#231F20;
	border:none windowtext 1.0pt;
	padding:0in;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB><img width=22 height=18 id="Immagine 1"
src="Ninlaro%20II-25%20EN%20PI%20clea_files/image001.gif" alt="BT_1000x858px"></span><span
lang=EN-GB>This medicinal product is subject to additional monitoring. This
will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section&nbsp;4.8
for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO 2.3&nbsp;mg
hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO
3&nbsp;mg hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO
4&nbsp;mg hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NINLARO 2.3&nbsp;mg
hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each capsule
contains 2.3&nbsp;mg of ixazomib (as 3.3&nbsp;mg of ixazomib citrate)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NINLARO
3&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each capsule contains 3&nbsp;mg of ixazomib (as 4.3&nbsp;mg of
ixazomib citrate) </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NINLARO
4&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each capsule contains 4&nbsp;mg of ixazomib (as 5.7&nbsp;mg of
ixazomib citrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hard capsule.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NINLARO
2.3&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Light pink, size
4 gelatin hard capsule, marked &#8220;Takeda&#8221; on the cap and
&#8220;2.3&nbsp;mg&#8221; on the body with black ink.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NINLARO
3&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Light grey, size 4 gelatin hard capsule, marked &#8220;Takeda&#8221;
on the cap and &#8220;3&nbsp;mg&#8221; on the body with black ink.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NINLARO
4&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Light orange,
size 3 gelatin hard capsule, marked &#8220;Takeda&#8221; on the cap and
&#8220;4&nbsp;mg&#8221; on the body with black ink.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO in
combination with lenalidomide and dexamethasone is indicated for the treatment
of adult patients with multiple myeloma who have received at least one prior
therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>Treatment must be initiated and
monitored under the supervision of a physician experienced in the management of
multiple myeloma. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>The recommended starting dose of ixazomib
is 4&nbsp;mg administered orally once a week on Days 1, 8, and 15 of a 28&#8209;day
treatment cycle. </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended starting dose of lenalidomide is 25&nbsp;mg
administered daily on Days 1 to 21 of a 28&#8209;day treatment cycle. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended starting dose of dexamethasone is 40&nbsp;mg
administered on Days 1, 8, 15, and 22 of a 28&#8209;day treatment cycle.</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 align=left
 style='border-collapse:collapse;border:none;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:13.4pt'>
  <td width=621 colspan=9 valign=top style='width:466.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Dosing schedule: Ixazomib taken with
  lenalidomide and dexamethasone</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=621 colspan=9 valign=top style='width:466.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>28&#8209;day cycle (a 4&#8209;week cycle)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 1</span></b></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 2</span></b></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 3</span></b></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 4</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 valign=top style='width:40.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 1</span></p>
  </td>
  <td width=69 valign=top style='width:51.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>2 to 7</span></p>
  </td>
  <td width=54 valign=top style='width:40.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 8</span></p>
  </td>
  <td width=69 valign=top style='width:51.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>9 to 14</span></p>
  </td>
  <td width=54 valign=top style='width:40.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 15</span></p>
  </td>
  <td width=69 valign=top style='width:51.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>16 to 21</span></p>
  </td>
  <td width=54 valign=top style='width:40.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 22</span></p>
  </td>
  <td width=69 valign=top style='width:51.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days 23 to 28</span></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Ixazomib</span></p>
  </td>
  <td width=54 style='width:40.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=69 style='width:51.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;background:#BFBFBF;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Lenalidomide</span></p>
  </td>
  <td width=54 style='width:40.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span><span lang=EN-GB>Daily</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span><span lang=EN-GB>Daily</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span><span lang=EN-GB>Daily</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=69 style='width:51.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;background:#BFBFBF;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Dexamethasone</span></p>
  </td>
  <td width=54 style='width:40.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;background:#BFBFBF;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=621 colspan=9 valign=top style='width:466.1pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt;font-family:Webdings'>a</span><span lang=EN-GB
  style='font-size:10.0pt'>=&nbsp;intake of medicinal product</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>For additional information regarding lenalidomide </span><span
lang=EN-GB>and dexamethasone, refer to the Summary of Product Characteristics
(SmPC) for these medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Prior to initiating a new cycle
of therapy:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=IT style='font-family:Symbol'>&middot;</span><span lang=IT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute
neutrophil count should be &#8805;&nbsp;1,000/mm<sup>3</sup></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=IT style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=IT>Platelet count should be &#8805;&nbsp;75,000/mm<sup>3</sup></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=IT style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=IT>Non&#8209;haematologic toxicities should, at the
physician&#8217;s discretion, generally be recovered to patient&#8217;s
baseline condition or &#8804;&nbsp;Grade&nbsp;1</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>Treatment
should be continued until disease progression or unacceptable toxicity.</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>Treatment with ixazomib in combination with
lenalidomide and dexamethasone for longer than 24&nbsp;cycles should be based
on an individual benefit risk assessment, as the data on the tolerability and
toxicity beyond 24&nbsp;cycles are limited (see section&nbsp;5.1).</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Delayed or missed doses </span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In the event that a ixazomib dose is delayed or missed, the dose
should be taken only if the next scheduled dose is &#8805;&nbsp;72 hours away. </span><span
lang=EN-GB>A missed dose should not be taken within 72 hours of the next
scheduled dose. A double dose should not be taken to make up for a missed dose.
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If a patient
vomits after taking a dose, the patient should not repeat the dose but should
resume dosing at the time of the next scheduled dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dose modifications</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The ixazomib
dose reduction steps are presented in Table 1 and the dose modification
guidelines are provided in </span><span lang=EN-GB>Table 2. <br>
<br>
</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name=Table1><b><span lang=EN-GB style='position:relative;top:.5pt'>Table 1</span></b></a><b><span
lang=EN-GB style='position:relative;top:.5pt'>: Ixazomib dose reduction steps</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:459.0pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=193 valign=top style='width:145.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Recommended starting dose* </span></p>
  </td>
  <td width=155 valign=top style='width:116.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>First reduction to</span></p>
  </td>
  <td width=145 valign=top style='width:108.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Second reduction to</span></p>
  </td>
  <td width=119 rowspan=2 style='width:88.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Discontinue</span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>4&nbsp;mg</span></p>
  </td>
  <td width=155 valign=top style='width:116.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>3&nbsp;mg</span></p>
  </td>
  <td width=145 valign=top style='width:108.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>2.3&nbsp;mg</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:11.5pt;text-indent:-.1in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>*Recommended
reduced dose of 3&nbsp;mg in the presence of moderate or severe hepatic
impairment, severe renal impairment or end&#8209;stage renal disease (ESRD)
requiring dialysis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>An alternating dose modification approach is recommended for ixazomib
and lenalidomide for overlapping toxicities of thrombocytopenia, neutropenia
and rash. For these toxicities, the first dose modification step is to
withhold/reduce lenalidomide. </span><span lang=EN-GB>Refer to the lenalidomide
SmPC, section&nbsp;4.2 for the dose reduction steps for these toxicities.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=615
 style='width:461.3pt;margin-left:7.6pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:15.7pt'>
   <td width=615 colspan=2 valign=top style='width:461.3pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   15.7pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
   name=Table2><b><span lang=EN-GB>Table 2</span></b></a><b><span lang=EN-GB>:
   Dose modifications guidelines for ixazomib in combination with lenalidomide
   and dexamethasone </span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:15.7pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Haematological toxicities</span></b></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoListParagraph style='margin:0in;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Recommended
  actions</span></b></p>
  </td>
 </tr>
 <tr style='height:15.8pt'>
  <td width=615 colspan=2 valign=top style='width:461.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Thrombocytopenia (platelet count)</span></b></p>
  </td>
 </tr>
 <tr style='height:31.95pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:31.95pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Platelet count
  <span style='position:relative;top:.5pt'>&lt;&nbsp;<span style='letter-spacing:
  .05pt'>30</span>,000/m<span style='letter-spacing:-.05pt'>m<sup>3</sup></span></span></span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.95pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Withhold
  ixazomib and lenalidomide until platelet count &#8805;&nbsp;30,000/mm<sup>3</sup>.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume lenalidomide at the next lower dose according to its SmPC
  and resume ixazomib at its most recent dose. </span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
  platelet count falls to &lt;&nbsp;30,000/mm<sup>3</sup> again, withhold ixazomib
  and lenalidomide until platelet count &#8805;&nbsp;30,000/mm<sup>3</sup>.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume ixazomib at the next lower dose and resume lenalidomide at
  its most recent dose.*</span></p>
  </td>
 </tr>
 <tr style='height:15.7pt'>
  <td width=615 colspan=2 valign=top style='width:461.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Neutropenia
  (absolute neutrophil count)</span></b></p>
  </td>
 </tr>
 <tr style='height:15.7pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='letter-spacing:.05pt'>Absolute neutrophil count</span><span
  lang=EN-GB> <span style='position:relative;top:.5pt'>&lt;&nbsp;</span>500/mm<sup>3</sup></span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Withhold
  ixazomib and lenalidomide until absolute neutrophil count is &#8805;&nbsp;500/mm<sup>3</sup>.
  Consider adding G&#8209;CSF as per clinical guidelines.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume lenalidomide at the next lower dose according to its
  prescribing information and resume ixazomib at its most recent dose. </span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
  absolute neutrophil count falls to &lt;&nbsp;500/mm<sup>3</sup> again,
  withhold ixazomib and lenalidomide until absolute neutrophil count is &#8805;
  500/mm<sup>3</sup>.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume ixazomib at the next lower dose and resume lenalidomide at
  its most recent dose.*</span></p>
  </td>
 </tr>
 <tr style='height:15.7pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Non&#8209;haematological
  toxicities</span></b></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoListParagraph style='margin:0in;line-height:normal'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Recommended actions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=2 valign=top style='width:461.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rash</span></b></p>
  </td>
 </tr>
 <tr style='height:31.75pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grade<sup>&#8224;</sup>
  2 or 3</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Withhold
  lenalidomide until rash recovers to &#8804;&nbsp;Grade&nbsp;1.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume lenalidomide at the next lower dose according to its SmPC. </span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
  Grade 2 or 3 rash occurs again, withhold ixazomib and lenalidomide until rash
  recovers to &#8804;&nbsp;Grade&nbsp;1.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume ixazomib at the next lower dose and resume lenalidomide at
  its most recent dose.*</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grade 4</span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discontinue
  treatment regimen.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=2 valign=top style='width:461.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Peripheral neuropathy</span></b></p>
  </td>
 </tr>
 <tr style='height:36.8pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:36.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Grade 1 peripheral neuropathy with pain or Grade 2 peripheral neuropathy</span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.8pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Withhold
  ixazomib until peripheral neuropathy recovers to &#8804;&nbsp;Grade&nbsp;1
  without pain or patient's baseline.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume ixazomib at its most recent dose.</span></p>
  </td>
 </tr>
 <tr style='height:36.7pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:36.7pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Grade 2 peripheral neuropathy with pain or Grade 3 peripheral neuropathy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.7pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Withhold
  ixazomib. Toxicities should, at the physician&#8217;s discretion, generally
  recover to patient&#8217;s baseline condition or &#8804;&nbsp;Grade&nbsp;1
  prior to resuming ixazomib.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Following
  recovery, resume ixazomib at the next lower dose.</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grade 4 peripheral
  neuropathy</span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discontinue
  treatment regimen.</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=615 colspan=2 valign=top style='width:461.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Other non&#8209;haematological toxicities</span></b></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=225 valign=top style='width:168.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Other Grade 3 or 4 non&#8209;haematological toxicities</span></p>
  </td>
  <td width=390 valign=top style='width:292.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Withhold
  ixazomib. Toxicities should, at the physician&#8217;s discretion, generally
  recover to patient&#8217;s baseline condition or at most&nbsp;Grade 1 prior
  to resuming ixazomib.</span></p>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.0pt;text-indent:-15.0pt;line-height:normal'><span
  style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
  attributable to ixazomib, resume ixazomib at the next lower dose following
  recovery.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:4.3pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt'>*</span><span lang=EN-GB style='font-size:
10.0pt'>For additional occurrences, alternate dose modification of lenalidomide
and ixazomib</span></p>

<p class=MsoNormal style='margin-left:4.3pt;line-height:normal'><sup><span
lang=EN-GB style='font-size:10.0pt'>&#8224;</span></sup><span lang=EN-GB
style='font-size:10.0pt'>Grading based on </span><span lang=EN-GB
style='font-size:10.0pt'>National Cancer Institute Common Terminology Criteria
(CTCAE) Version 4.03</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Concomitant
medicinal products</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Antiviral
prophylaxis should be considered in patients being treated with ixazomib to
decrease the risk of herpes zoster reactivation. Patients included in studies
with ixazomib who received antiviral prophylaxis had a lower incidence of
herpes zoster infection compared to patients who did not receive prophylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thromboprophylaxis
is recommended in patients being treated with ixazomib in combination with
lenalidomide and dexamethasone, and should be based on an assessment of the
patient&#8217;s underlying risks and clinical status. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For other
concomitant medicinal products that may be required, refer to the current
lenalidomide and dexamethasone SmPC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><a name="_Toc360524842"><u><span lang=EN-GB
style='font-size:11.0pt;font-weight:normal'>Special patient populations</span></u></a></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-style:normal'>&nbsp;</span></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>Elderly</span></i></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>&nbsp;</span></i></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;font-weight:normal;text-decoration:
none'>No dose adjustment of ixazomib is required for patients over 65&nbsp;years
of age. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Discontinuations in patients &gt;&nbsp;75
years of age were reported in 13 patients (28%) in the ixazomib regimen and 10
patients (16%) in the placebo regimen. Cardiac arrhythmias in patients &gt;&nbsp;75
years of age were observed in 10 patients (21%) in the ixazomib regimen and 9
patients (15%) in the placebo regimen. </p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>Hepatic
impairment</span></i></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment of ixazomib is required for patients with mild hepatic impairment
(total bilirubin &#8804;&nbsp;upper limit of normal (ULN) and aspartate
aminotransferase&nbsp;(AST) &gt;&nbsp;ULN or total bilirubin &gt;&nbsp;1&#8209;1.5&nbsp;x&nbsp;ULN
and any AST). The reduced dose of 3&nbsp;mg is recommended in patients with moderate
(total bilirubin &gt;&nbsp;1.5&#8209;3&nbsp;x&nbsp;ULN) or severe (total
bilirubin &gt;&nbsp;3&nbsp;x&nbsp;ULN) hepatic impairment (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>Renal
impairment</span></i></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment of ixazomib is required for patients with mild or moderate renal
impairment (creatinine clearance &#8805;&nbsp;</span><span lang=EN-GB>30&nbsp;mL/min).
The reduced dose of 3&nbsp;mg is recommended in patients with severe renal impairment
(creatinine clearance &lt;&nbsp;30&nbsp;mL/min) or end&#8209;stage renal
disease (ESRD) requiring dialysis. Ixazomib is not dialyzable and, therefore,
can be administered without regard to the timing of dialysis (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Refer to the
lenalidomide SmPC for dosing recommendations in patients with renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>Paediatric population</span></i></p>

<p class=CCDSMinorSubheading2 align=left style='margin-top:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;font-weight:normal;text-decoration:none'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of ixazomib in children below 18&nbsp;years
of age have not been established. No data are available.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ixazomib is for oral use.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Ixazomib should be taken at approximately the same time on days 1,
8, and 15 of each treatment cycle at least 1 hour before or at least 2 hours
after food (see section&nbsp;5.2). The capsule should be swallowed whole with
water. It should not be crushed, chewed, or opened (see section&nbsp;6.6). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As ixazomib is administered in combination with lenalidomide and
dexamethasone, refer to the SmPC for these medicinal products for additional
contraindications.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As ixazomib is administered in combination with lenalidomide and dexamethasone,
refer to the SmPC for these medicinal products for additional special warnings
and precautions for use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'>Thrombocytopenia</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Thrombocytopenia
has been reported with </span><span lang=EN-GB style='color:windowtext;
font-style:normal'>ixazomib</span><span lang=EN-GB style='color:windowtext;
font-style:normal'> (see section&nbsp;4.8) with platelet nadirs typically
occurring between Days 14&#8209;21 of each 28&#8209;day cycle and recovery to
baseline by the start of the next cycle (see section&nbsp;4.8). </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Platelet
counts should be monitored at least monthly during ixazomib treatment. </span><span
lang=EN-GB style='color:windowtext;font-style:normal'>More frequent monitoring should
be considered during the first three cycles as per the lenalidomide SmPC. </span><span
lang=EN-GB style='color:windowtext;font-style:normal'>Thrombocytopenia can be
managed with dose modifications (see section&nbsp;4.2) and platelet
transfusions as per standard medical guidelines. </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'>Gastrointestinal toxicities</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Diarrhoea,
constipation, nausea and vomiting have been reported with ixazomib,
occasionally requiring use of antiemetic and antidiarrhoeal medicinal products and
supportive care (see section&nbsp;4.8). The dose should be adjusted for severe
(Grade 3&#8209;4) symptoms (see section&nbsp;4.2).</span><span lang=EN-GB
style='color:windowtext;font-style:normal'> In case of severe gastrointestinal
events, monitoring of serum potassium level is recommended.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Peripheral neuropathy</span></u></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif'>Peripheral
neuropathy has been reported with ixazomib (see section&nbsp;4.8).<i> </i></span><span
style='font-family:"Times New Roman",serif'>The patient should be monitored for
symptoms of peripheral neuropathy. Patients experiencing new or worsening
peripheral neuropathy may require dose modification </span><span
style='font-family:"Times New Roman",serif'>(see section&nbsp;4.2)</span><span
style='font-family:"Times New Roman",serif'>.</span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'>Peripheral oedema</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Peripheral
oedema has been reported with ixazomib (see section&nbsp;4.8). The patient
should be e</span><span lang=EN-GB>valuated for underlying causes and provide
supportive care, as necessary. The dose of dexamethasone should be adjusted per
its prescribing information or ixazomib for Grade</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>3</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>or</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4 symptoms </span><span lang=EN-GB>(see
section&nbsp;4.2)</span><span lang=EN-GB>.</span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span style='font-family:
"Times New Roman",serif'>Cutaneous reactions</span></u></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rash has been
reported with ixazomib (see section&nbsp;4.8). </span><span
class=MsoCommentReference><span lang=EN-GB>Rash should be managed with supportive
care or with dose modification if Grade</span></span><span lang=EN-GB>&nbsp;</span><span
class=MsoCommentReference><span lang=EN-GB>2 or higher </span></span><span
lang=EN-GB>(see section&nbsp;4.2)</span><i><span lang=EN-GB>.</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span style='font-family:
"Times New Roman",serif'>Thrombotic microangiopathy</span></u></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
thrombotic microangiopathy (TMA), </span>including thrombotic thrombocytopenic
purpura (TTP), <span lang=EN-GB>have been reported in patients who received
ixazomib. Some of these events have been fatal. Signs and symptoms of TMA
should be monitored for. If the diagnosis is suspected, stop ixazomib and
evaluate patients for possible TMA. If the diagnosis of TMA is excluded,
ixazomib can be restarted. The safety of reinitiating ixazomib therapy in
patients previously experiencing TMA is not known.</span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><u><span style='font-family:
"Times New Roman",serif'>Hepatotoxicity</span></u></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=X-NONE
style='font-size:11.0pt'>Drug&#8209;induced liver injury, hepatocellular
injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have been uncommonly
reported with ixazomib (see section&nbsp;4.8). </span><span style='font-size:
11.0pt'>Hepatic enzymes should be m</span><span class=MsoCommentReference><span
lang=X-NONE style='font-size:11.0pt'>onitored regularly and </span></span><span
class=MsoCommentReference><span style='font-size:11.0pt'>the dose should be
adjusted</span></span><span class=MsoCommentReference><span lang=X-NONE
style='font-size:11.0pt'> for Grade</span></span><span lang=X-NONE
style='font-size:11.0pt'>&nbsp;</span><span class=MsoCommentReference><span
lang=X-NONE style='font-size:11.0pt'>3</span></span><span lang=X-NONE
style='font-size:11.0pt'>&nbsp;</span><span class=MsoCommentReference><span
lang=X-NONE style='font-size:11.0pt'>or</span></span><span lang=X-NONE
style='font-size:11.0pt'>&nbsp;</span><span class=MsoCommentReference><span
lang=X-NONE style='font-size:11.0pt'>4 symptoms </span></span><span
lang=X-NONE style='font-size:11.0pt'>(see section&nbsp;4.2)</span><i><span
lang=X-NONE style='font-size:11.0pt'>.</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women should
avoid becoming pregnant while being treated with ixazomib. </span><span
lang=EN-GB>If ixazomib is used during pregnancy or if the patient becomes
pregnant while taking ixazomib, the patient should be apprised of the potential
hazard to the foetus. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women of
childbearing potential must use highly effective contraception while taking ixazomib
and for 90 days after stopping treatment (see sections&nbsp;4.5 and 4.6). Women
using hormonal contraceptives should additionally use a barrier method of
contraception<b>.</b></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posterior reversible encephalopathy syndrome</span></u><b><span
lang=EN-GB> </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Posterior reversible encephalopathy syndrome (PRES) has occurred in
patients receiving ixazomib. PRES is a rare, reversible, neurological disorder
which can present with seizure, hypertension, headache, altered consciousness,
and visual disturbances. Brain imaging, preferably Magnetic Resonance Imaging,
is used to confirm the diagnosis. In patients developing PRES, discontinue ixazomib.
</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Strong CYP3A inducers</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Strong inducers
may reduce the efficacy of ixazomib, therefore the concomitant use of strong
CYP3A inducers such as carbamazepine, phenytoin, rifampicin and St.
John&#8217;s Wort (<i>Hypericum perforatum</i>), should be avoided (see sections&nbsp;4.5
and 5.2). Closely monitor patients for disease control if co&#8209;administration
with a strong CYP3A inducer cannot be avoided.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pharmacokinetic interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>CYP inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co&#8209;administration
of ixazomib with clarithromycin, a strong CYP3A inhibitor, did not result in a
clinically meaningful change in the systemic exposure of ixazomib. Ixazomib C<sub>max</sub>
was decreased by 4% and AUC was increased by 11%. Therefore, no dose
modification is required for ixazomib with co&#8209;administration of strong
CYP3A inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co&#8209;administration
of ixazomib with strong CYP1A2 inhibitors did not result in a clinically
meaningful change in the systemic exposure of ixazomib based on the results of
a population pharmacokinetic (PK) analysis. Therefore, no dose modification is
required for ixazomib with co&#8209;administration of strong CYP1A2 inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>CYP inducers</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co&#8209;administration
of ixazomib with rifampicin decreased ixazomib C<sub>max</sub> by 54% and AUC
by 74%. Therefore, co&#8209;administration of strong CYP3A inducers with
ixazomib is not recommended (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effect of ixazomib on other medicinal products</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib is not
a reversible or a time&#8209;dependent inhibitor of CYPs 1A2, 2B6, 2C8, 2C9,
2C19, 2D6, or 3A4/5. Ixazomib did not induce CYP1A2, CYP2B6, and CYP3A4/5
activity or corresponding immunoreactive protein levels. Ixazomib is not
expected to produce drug&#8209;drug interactions via CYP&nbsp;inhibition or induction.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Transporter&#8209;based interactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ixazomib is a low affinity substrate of P&#8209;gp. Ixazomib is not
a substrate of BCRP, MRP2 or hepatic OATPs. Ixazomib is not an inhibitor of P&#8209;gp,
BCRP, MRP2, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, or MATE2&#8209;K. Ixazomib
is not expected to cause transporter&#8209;mediated drug&#8209;drug
interactions. </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Oral
contraceptives</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When ixazomib is
administered together with dexamethasone, which is known to be a weak to
moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk
for reduced efficacy of oral contraceptives needs to be considered. Women using
hormonal contraceptives should additionally use a barrier method of
contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As ixazomib is administered in combination with lenalidomide and
dexamethasone, refer to the SmPC for these medicinal products for additional
information on fertility, pregnancy and lactation.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential/Contraception in males and females</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Male and female
patients who are able to have children must use effective contraceptive
measures during and for 90&nbsp;days following treatment. Ixazomib is not
recommended in women of childbearing potential not using contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>When ixazomib is administered
together with dexamethasone, which is known to be a weak to moderate inducer of
CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy
of oral contraceptives needs to be considered. Therefore, women using oral
hormonal contraceptives should additionally use a barrier method of
contraception.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib is not
recommended during pregnancy as it can cause foetal harm when administered to a
pregnant woman. Therefore, women should avoid becoming pregnant while being
treated with ixazomib. </span></p>

<h4 style='margin:0in;line-height:normal;page-break-after:auto'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>&nbsp;</span></h4>

<h4 style='margin:0in;line-height:normal;page-break-after:auto'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>There are no data for the use of ixazomib in pregnant
women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3).</span></h4>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib is
given in combination with lenalidomide. Lenalidomide is structurally related to
thalidomide. Thalidomide is a known human teratogenic active substance that
causes severe life&#8209;threatening birth defects. If lenalidomide is taken
during pregnancy, a teratogenic effect in humans is expected. The conditions of
the Pregnancy Prevention Programme for lenalidomide must be fulfilled for all
patients unless there is reliable evidence that the patient does not have
childbearing potential. Please refer to the current lenalidomide SmPC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether ixazomib</span><span lang=EN-GB> or its metabolites</span><span
lang=EN-GB> are excreted in human milk. No animal data are available. </span><span
lang=EN-GB>A risk to newborns/infants cannot be excluded and therefore </span><span
lang=EN-GB>breast&#8209;feeding should be discontinued. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib will be
given in combination with lenalidomide and breast&#8209;feeding should be
stopped because of the use of lenalidomide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fertility
studies have not been conducted with ixazomib (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib has
minor influence on the ability to drive or use machines. Fatigue and dizziness
have been observed in clinical trials. Patients should be advised not to drive
or operate machines if they experience any of these symptoms.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As ixazomib is administered in combination with lenalidomide and
dexamethasone, refer to the SmPC for these medicinal products for additional
undesirable effects.</span></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext;font-style:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext;font-style:
normal'>Summary of the safety profile</span></u></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety profile of NINLARO is based on available clinical trial
data and post&#8209;marketing experience to date. Frequencies of adverse
reactions described below and in Table&nbsp;3 have been determined based on
data generated from clinical studies.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Unless
otherwise noted, the data presented below is </span><span lang=EN-GB
style='color:windowtext;font-style:normal'>the pooled safety data from the
pivotal, Phase 3, global C16010 study (n=720) and the double&#8209;blind,
placebo&#8209;controlled C16010 China Continuation Study (n=115). </span><span
lang=EN-GB style='color:windowtext;font-style:normal'>The most frequently
reported adverse reactions (&#8805;&nbsp;20%) across 417 patients treated within
the ixazomib regimen and 418 patients within the placebo regimen were diarrhoea
(39% vs. 32%), thrombocytopenia (33% vs. 21%), neutropenia (33% vs. 30%), constipation
(30% vs. 22%), peripheral neuropathy (25% vs. 20%), nausea (23% vs. 18%),
peripheral oedema (23% vs. 17%), vomiting (20% vs. 10%) and upper respiratory
tract infection (21% vs. 16%). Serious adverse reactions reported in &#8805;&nbsp;2%
of patients included thrombocytopenia (2%) and diarrhoea (2%). </span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'>Tabulated list of adverse reactions</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext;font-style:normal'>The following convention is used for
the classification of the frequency of an adverse drug reaction (ADR): very
common (&#8805;&nbsp;1/10); common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10);
uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be
estimated from the available data). Within each system organ class, the ADRs
are ranked by frequency, with the most frequent reactions first.</span><span
lang=EN-GB style='font-style:normal'> </span><span lang=EN-GB style='color:
windowtext;font-style:normal'>Within each frequency grouping, adverse reactions
are presented in order of decreasing seriousness.</span></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext;font-style:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name=Table3><b><span lang=EN-GB>Table 3</span></b></a><b><span lang=EN-GB>:
Adverse reactions in patients treated with ixazomib in combination with lenalidomide
and dexamethasone (all grades, grade 3 and grade 4) </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=608
 style='width:455.95pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>System organ class / Adverse reaction</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Adverse reactions (all grades)</span></b></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Grade 3 adverse reactions</span></b></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Grade 4 adverse reactions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Infections and infestations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Upper respiratory tract infection</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Herpes zoster</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Thrombocytopenia*</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common</span></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Neutropenia*</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common</span></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Thrombotic microangiopathy</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Thrombotic thrombocytopenic purpura</span><sup><span lang=EN-GB>&#8224;</span></sup></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tumour lysis syndrome</span><sup><span lang=EN-GB>&#8224;</span></sup></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rare</span></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Peripheral
  neuropathies*</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Posterior
  reversible encephalopathy disorders*</span><sup><span lang=EN-GB>&#8224;</span></sup></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Transverse
  myelitis</span><sup><span lang=EN-GB>&#8224;</span></sup></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Gastrointestinal
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nausea</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vomiting</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Constipation</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rash*</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Stevens&#8209;Johnson
  syndrome</span><sup><span lang=EN-GB>&#8224;</span></sup></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Acute febrile </span><span
  lang=FR>neutrophilic dermatosis</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Back pain</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common </span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=608 colspan=4 valign=top style='width:455.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oedema
  peripheral</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=154 valign=top style='width:115.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=135 valign=top style='width:101.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='font-size:10.0pt'>Note: ADRs included as preferred terms are based on
MedDRA version 16.0.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:10.0pt'>*Represents a pooling of preferred terms</span></p>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB
style='font-size:10.0pt'>&#8224;</span></sup><span lang=EN-GB style='font-size:
10.0pt'>Reported outside of the Phase<sup> </sup>3 studies</span></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext;font-style:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'>Description of selected adverse
reactions</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Discontinuations</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>For
each adverse reaction, one or more of the three medicinal products was
discontinued in &#8804;&nbsp;1% of patients in the ixazomib regimen.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext'>Thrombocytopenia</span></u></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Three
percent of patients in the ixazomib regimen and 1% of patients in the placebo
regimen had a platelet count &#8804;&nbsp;10,000/mm<sup>3</sup></span><span
lang=EN-GB style='color:windowtext'> </span><span lang=EN-GB style='color:windowtext;
font-style:normal'>during treatment</span><span lang=EN-GB style='color:windowtext;
font-style:normal'>. Less than 1% of patients in both regimens had a platelet
count &#8804;&nbsp;5,000/mm<sup>3</sup></span><span lang=EN-GB
style='color:windowtext;font-style:normal'> during treatment</span><span
lang=EN-GB style='color:windowtext;font-style:normal'>. Thrombocytopenia
resulted in discontinuation of one or more of the three medicinal products in
&lt;&nbsp;1% of patients in the ixazomib regimen and 1% of patients in the
placebo regimen.</span><span lang=EN-GB style='color:windowtext'> </span><span
lang=EN-GB style='color:windowtext;font-style:normal'>Thrombocytopenia did not
result in an increase in haemorrhagic events or platelet transfusions.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Gastrointestinal toxicities</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Diarrhoea
resulted in discontinuation of one or more of the three medicinal products in
1% of patients in the ixazomib regimen and &lt;&nbsp;1% of patients in the
placebo regimen.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Rash</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rash occurred in
18% of patients in the ixazomib regimen compared to 10% of patients in the
placebo regimen. The most common type of rash reported in both regimens was maculo&#8209;papular
and macular rash. Grade&nbsp;3 rash was reported in 2% of patients in the ixazomib
regimen compared to 1%&nbsp;of patients in the placebo regimen. Rash resulted
in discontinuation of one or more of the three medicinal products in &lt;&nbsp;1%
of patients in both regimens.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Peripheral neuropathy</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Peripheral
neuropathy occurred in 25% of patients in the ixazomib regimen compared to 20%
of patients in the placebo regimen. Grade 3 adverse reactions of peripheral
neuropathy were reported in 2% of patients in both regimens. The most commonly
reported reaction was peripheral sensory neuropathy (16%&nbsp;and 12% in the ixazomib
and placebo regimen, respectively). Peripheral motor neuropathy was not
commonly reported in either regimen (&lt;&nbsp;1%). Peripheral neuropathy
resulted in discontinuation of one or more of the three medicinal products in
1% of patients in the ixazomib regimen compared to &lt;&nbsp;1% of patients in
the placebo regimen.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Eye disorders </span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Eye
disorders were reported with many different preferred terms but in aggregate,
the frequency was 24% in patients in the ixazomib regimen and 15% of patients
in the placebo regimen. The most common adverse reactions were blurred vision (5%
in the ixazomib regimen and 4% in the placebo regimen), dry eye (4% in the ixazomib
regimen and 1% in the placebo regimen), conjunctivitis (5% in the ixazomib
regimen and 1% in the placebo regimen) and cataract (4% in the ixazomib regimen
and 5% in the placebo regimen). Grade 3 adverse reactions were reported in 2%
of patients in both regimens.</span></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:windowtext'>Other adverse reactions</span></u></p>

<p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the pooled
dataset from the pivotal, Phase 3, global C16010 study (n=720) and the double&#8209;blind,
placebo&#8209;controlled, C16010 China Continuation Study (n=115), the
following adverse reactions occurred with a similar rate between the ixazomib
and placebo regimens: fatigue (26% vs. 24%), decreased appetite (12% vs. 9%),
hypotension (4% each), heart failure</span><sup>&#8224;</sup><span lang=EN-GB>
(3% each), arrhythmia</span><sup>&#8224;</sup><span lang=EN-GB> (12% vs. 11%),
and liver impairment including enzyme changes</span><sup>&#8224;</sup><span
lang=EN-GB> (8% vs. 6%).</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span style='color:windowtext;font-style:normal'>The
frequency of severe (Grade&nbsp;3&#8209;4) events of hypokalaemia was higher in
the ixazomib regimen (5%) than the placebo regimen (&lt;&nbsp;1%). </span></p>

<p class=MsoBodyText><span style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText><span style='color:windowtext;font-style:normal'>Fungal
and viral pneumonia resulting in fatal outcome were rarely reported in patients
given the ixazomib, lenalidomide and dexamethasone combination.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup>&#8224; </sup><span
lang=EN-GB>Standardised MedDRA Queries (SMQs)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
silver'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix V</span></a><span style='background:silver'>.</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Overdose has been reported in patients taking NINLARO. Symptoms of
overdose are generally consistent with the known risks of NINLARO (see section
4.8). Overdose of 12&nbsp;mg (taken at one time) has resulted in serious
adverse events, such as severe nausea, aspiration pneumonia, multiple organ
failure and death.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
known specific antidote for ixazomib overdose. In the event of an overdose,
monitor the patient closely </span>for adverse reactions (section&nbsp;4.8) <span
lang=EN-GB>and provide appropriate supportive care. Ixazomib is not dialyzable
(see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdoses were
most common in patients starting treatment with NINLARO. The importance of
carefully following all dosage instructions should be discussed with patients
starting treatment. </span><span lang=EN-GB>Instruct patients to take the
recommended dosage as directed because overdose has led to deaths.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX50</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Ixazomib citrate, a prodrug, is a substance that rapidly hydrolyses
under physiological conditions to its biologically active form, ixazomib. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib is an
oral, highly selective and reversible proteasome inhibitor. Ixazomib
preferentially binds and inhibits the chymotrypsin&#8209;like activity of the
beta 5 subunit of the 20S proteasome. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib induced
apoptosis of several tumour cell types <i>in&nbsp;vitro</i>. Ixazomib
demonstrated <i>in&nbsp;vitro</i> cytotoxicity against myeloma cells from
patients who had relapsed after multiple prior therapies, including bortezomib,
lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide
demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. <i>In&nbsp;vivo</i>,
ixazomib demonstrated antitumour activity in various tumour xenograft models,
including models of multiple myeloma. <i>In&nbsp;vitro</i>, ixazomib affected
cell types found in the bone marrow microenvironment including vascular
endothelial cells, osteoclasts and osteoblasts.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Cardiac electrophysiology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib did not
prolong the QTc interval at clinically relevant exposures based on the results
of a pharmacokinetic&#8209;pharmacodynamic analysis of data from 245 patients.
At the 4&nbsp;mg dose, mean&nbsp;change from baseline in QTcF was estimated to
be 0.07&nbsp;msec (90% CI; &#8209;0.22, 0.36) from the model based analysis.
There was no discernible relationship between ixazomib concentration and the RR
interval suggesting no clinically meaningful effect of ixazomib on heart rate.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=CM36><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
efficacy and safety of ixazomib in combination with lenalidomide and
dexamethasone was evaluated in an international randomised, double&#8209;blind,
placebo&#8209;controlled, multicenter Phase 3 superiority study (C16010) in
patients with relapsed and/or refractory multiple myeloma who had received at
least one prior therapy. A total of 722 patients (intent&#8209;to-treat [ITT] population)
were randomised in a 1:1 ratio to receive either the combination of ixazomib,
lenalidomide, and dexamethasone (N=360; ixazomib regimen) or placebo, lenalidomide
and dexamethasone (N=362;</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>placebo
regimen) until disease progression or unacceptable toxicity. Patients enrolled
in the trial had multiple myeloma that was refractory, including primary
refractory, had relapsed after prior therapy, or had relapsed and was
refractory to any prior therapy. Patients that changed therapies prior to
disease progression were eligible for enrolment, as well as those with
controlled cardiovascular conditions. </span><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>The Phase 3 study excluded patients who
were refractory to lenalidomide or proteasome inhibitors and patients who
received more than three prior therapies. </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>For the purposes
of this study, refractory disease was defined as disease progression on
treatment or progression within 60 days after the last dose of lenalidomide or
a proteasome inhibitor. </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>As
data are l</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>imited
in these patients, a careful risk&#8209;benefit assessment is recommended
before initiating the ixazomib regimen.</span></p>

<p class=CM36><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=CM36><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Thromboprophylaxis
was recommended for all patients in both treatment groups according to the
lenalidomide SmPC. Concomitant medicinal products, such as antiemetic,
antiviral, and antihistamine medicinal products were given to patients at the
physician's discretion as prophylaxis and/or management of symptoms. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients received ixazomib 4&nbsp;mg or placebo on Days 1, 8, and 15
plus lenalidomide (25&nbsp;mg) on Days&nbsp;1 through 21 and dexamethasone
(40&nbsp;mg) on Days 1, 8, 15, and 22 of a 28&#8209;day cycle. Patients with
renal impairment received a starting dose of lenalidomide according to its
SmPC. Treatment continued until disease progression or unacceptable toxicities.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=CM36><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
baseline demographics and disease characteristics were balanced and comparable
between the study regimens. </span><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The median age was 66&nbsp;years, range 38&#8209;91&nbsp;years;
58% of patients were older than 65&nbsp;years. Fifty seven percent of patients
were male. Eighty five percent of the population was White, 9% Asian and 2% Black.
Ninety three percent of patients had an ECOG performance status of 0&#8209;1
and 12% had baseline ISS stage III disease (N=90). Twenty five percent of
patients had a creatinine clearance of &lt;&nbsp;60&nbsp;mL/min. Twenty three
percent of patients had light chain disease and 12% of patients had measurable
disease by free light chain assay only. Nineteen percent had high&#8209;risk
cytogenetic abnormalities (del[17], t[4;14], t[14;16]) (N=137), 10% had del(17)
(N=69) and 34% had 1q amplification (1q21) (N=247). Patients received one to
three prior therapies (median of 1) including prior treatment with bortezomib
(69%), carfilzomib (&lt;&nbsp;1%), thalidomide (45%), lenalidomide (12%),
melphalan (81%). Fifty seven percent of patients had undergone prior stem cell
transplantation. Seventy seven percent of patients relapsed after prior therapies
and 11% were refractory to prior therapies. Primary refractory, defined as best
response of stable disease or disease progression on all prior therapies, was
documented in 6% of patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The primary endpoint was progression&#8209;free survival (PFS)
according to the 2011 International Myeloma Working Group (IMWG) Consensus
Uniform Response Criteria as assessed by a blinded independent review committee
(IRC) based on central laboratory results. Response was assessed every 4&nbsp;weeks
until disease progression. At the primary analysis (median follow up of 14.7
months and a median of 13 cycles), PFS was statistically significantly
different between the treatment arms. PFS results are summarised in Table 4 and
Figure 1. The improvement in PFS in the ixazomib regimen was supported by
improvements in overall response rate.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table 4: Progression free survival and response Results in multiple myeloma
patients treated with ixazomib or placebo in combination with lenalidomide and dexamethasone
(intent&#8209;to-treat population)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:154.65pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=207 colspan=3 valign=top style='width:155.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Ixazomib + Lenalidomide and
  Dexamethasone</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(N = 360)</span></p>
  </td>
  <td width=207 valign=top style='width:155.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Placebo + Lenalidomide and
  Dexamethasone</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(N = 362)</span></p>
  </td>
 </tr>
 <tr>
  <td width=620 colspan=5 valign=top style='width:465.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Progression&#8209;Free Survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Events, n (%)</span></p>
  </td>
  <td width=207 colspan=3 style='width:155.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>129 (36)</span></p>
  </td>
  <td width=207 style='width:155.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>157 (43)</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Median (months)</span></p>
  </td>
  <td width=207 colspan=3 valign=top style='width:155.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>20.6</span></p>
  </td>
  <td width=207 valign=top style='width:155.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>14.7</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>p&#8209;value*</span></p>
  </td>
  <td width=414 colspan=4 valign=top style='width:310.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>0.012</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Hazard Ratio<sup>&#8224;</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=414 colspan=4 valign=top style='width:310.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>0.74</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(0.59, 0.94)</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 colspan=2 valign=top style='width:155.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Overall Response Rate</span></b><sup><span lang=EN-GB>&#8225;</span></sup><b><span
  lang=EN-GB>, n (%) </span></b></p>
  </td>
  <td width=206 valign=top style='width:154.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>282 (78.3)</span></p>
  </td>
  <td width=207 colspan=2 valign=top style='width:155.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>259 (71.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=620 colspan=5 valign=top style='width:465.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Response Category, n (%)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=207 colspan=2 valign=top style='width:155.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Complete Response </span></p>
  </td>
  <td width=206 valign=top style='width:154.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>42 (11.7)</span></p>
  </td>
  <td width=207 colspan=2 valign=top style='width:155.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>24 (6.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 colspan=2 valign=top style='width:155.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Very Good Partial Response </span></p>
  </td>
  <td width=206 valign=top style='width:154.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>131 (36.4)</span></p>
  </td>
  <td width=207 colspan=2 valign=top style='width:155.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>117 (32.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 colspan=2 valign=top style='width:155.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Partial Response </span></p>
  </td>
  <td width=206 valign=top style='width:154.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>109 (30.3)</span></p>
  </td>
  <td width=207 colspan=2 valign=top style='width:155.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>118 (32.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=620 colspan=5 valign=top style='width:465.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Time to Response, months</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=207 colspan=2 valign=top style='width:155.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Median</span></p>
  </td>
  <td width=206 valign=top style='width:154.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>1.1</span></p>
  </td>
  <td width=207 colspan=2 valign=top style='width:155.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>1.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=620 colspan=5 valign=top style='width:465.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Duration of Response</span></b><sup><span lang=EN-GB>&sect;</span></sup><b><span
  lang=EN-GB>, months</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=207 colspan=2 valign=top style='width:155.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Median</span></p>
  </td>
  <td width=206 valign=top style='width:154.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>20.5</span></p>
  </td>
  <td width=207 colspan=2 valign=top style='width:155.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>15.0</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=206 style='border:none'></td>
  <td width=0 style='border:none'></td>
  <td width=206 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=207 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:4.3pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-size:10.0pt'>*P&#8209;value is based on the
stratified log&#8209;rank test.</span></p>

<p class=MsoNormal style='margin-left:13.65pt;text-indent:-9.35pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB style='font-size:10.0pt'>&#8224;</span></sup><span
lang=EN-GB style='font-size:10.0pt'>Hazard ratio is based on a stratified
Cox&#8217;s proportional hazard regression model. A hazard ratio less than 1
indicates an advantage for the ixazomib regimen.</span></p>

<p class=MsoNormal style='margin-left:13.65pt;text-indent:-9.35pt;line-height:
normal;text-autospace:none'><a name=footnote-14><sup><span lang=EN-GB
style='font-size:10.0pt'>&#8225;</span></sup></a><span lang=EN-GB
style='font-size:10.0pt'>ORR=CR+VGPR+PR</span></p>

<p class=MsoNormal style='margin-left:13.65pt;text-indent:-9.35pt;line-height:
normal;text-autospace:none'><a name=footnote-15><sup><span lang=EN-GB
style='font-size:10.0pt'>&sect;</span></sup></a><span lang=EN-GB
style='font-size:10.0pt'>Based on responders in the response&#8209;evaluable
population</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Figure 1: Kaplan&#8209;Meier plot of progression&#8209;free
survival in the intent&#8209;to-treat population</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB><img width=605 height=321
src="Ninlaro%20II-25%20EN%20PI%20clea_files/image002.gif"></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A planned
interim analysis for overall survival (OS) at a median follow up of 23&nbsp;months
was conducted with 35% of the required number of deaths for final OS analysis
in the ITT population; there were 81&nbsp;deaths in the ixazomib regimen and
90&nbsp;deaths in the placebo regimen. Median overall survival was not reached
in either regimen. At this analysis, estimated median PFS was 20&nbsp;months in
the ixazomib regimen and 15.9&nbsp;months in the placebo regimen (HR=0.82 [95%
CI (0.67, 1.0)]) in the ITT population.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A randomised, double&#8209;blind, placebo&#8209;controlled Phase 3
study was conducted in China (N=115) with a similar study design and
eligibility criteria. Many of the patients enrolled in the study had advanced
disease with Durie&#8209;Salmon Stage III (69%) at initial diagnosis and a
treatment history of receiving at least 2 prior therapies (60%) and being
thalidomide refractory (63%). At the primary analysis (median follow up of 8
months and a median of 6 cycles), the median PFS was 6.7 months in the ixazomib
regimen compared to 4 months in the placebo regimen (p&#8209;value=0.035,
HR=0.60). At the final analysis for OS at a median follow up of 19.8 months, </span><span
lang=EN-GB>OS was improved for patients treated in the ixazomib regimen
compared with placebo </span><span lang=EN-GB>[p&#8209;value=0.0014, HR=0.42,</span><span
lang=EN-GB> 95% CI: 0.242, 0.726</span><span lang=EN-GB> ]).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>As multiple myeloma is a heterogeneous disease, benefit
may vary across subgroups in the Phase 3 study (C16010) (see Figure 2). </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Figure 2: Forest plot of progression&#8209;free
survival in subgroups</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB><img border=0 width=605 height=522 id="Picture 3"
src="Ninlaro%20II-25%20EN%20PI%20clea_files/image003.gif"></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the Phase 3 study </span><span lang=EN-GB>(C16010), 10&nbsp;patients
(5 in each treatment regimen) had severe renal impairment at baseline. Of the
5&nbsp;patients in the ixazomib regimen, one patient had a confirmed partial
response and 3 confirmed stable disease (however 2 were unconfirmed partial
response and 1 was an unconfirmed very good partial response). Of the
5&nbsp;patients in the placebo regimen, 2 had a confirmed very good partial
response.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Quality of life as
assessed by global health scores (EORTC QLQ&#8209;C30 and MY&#8209;20) was
maintained during treatment and was similar in both treatment regimens in the
Phase 3 study (C16010).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ixazomib in all subsets of the paediatric population in multiple myeloma
(see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After oral
administration, peak plasma concentrations of ixazomib were achieved at
approximately one hour after dosing. The mean absolute oral bioavailability is
58%. Ixazomib AUC increases in a dose proportional manner over a dose range of
0.2&#8209;10.6&nbsp;mg.<i> </i></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
with a high&#8209;fat meal decreased ixazomib AUC by 28% compared with
administration after an overnight fast (see section&nbsp;4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>Ixazomib is 99% bound to plasma proteins and
distributes into red blood cells with a blood&#8209;to&#8209;plasma AUC ratio of&nbsp;10.
The steady&#8209;state volume of distribution is 543&nbsp;L. </span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>After oral administration of a radiolabeled dose,
70% of total drug&#8209;related material in plasma was accounted for by
ixazomib. Metabolism by multiple CYP enzymes and non&#8209;CYP proteins is
expected to be the major clearance mechanism for ixazomib. At clinically
relevant ixazomib concentrations, <i>in&nbsp;vitro</i> studies using human cDNA&#8209;expressed
cytochrome P450&nbsp;isozymes</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt;font-weight:normal'>indicate that no
specific CYP&nbsp;isozyme predominantly contributes to ixazomib metabolism and
non&#8209;CYP proteins contribute to overall metabolism. At concentrations
exceeding those observed clinically, ixazomib was metabolized by multiple CYP
isoforms with estimated relative contributions of 3A4 (42.3%), 1A2 (26.1%),
2B6&nbsp;(16.0%), 2C8 (6.0%), 2D6 (4.8%), 2C19 (4.8%) and 2C9 (&lt;&nbsp;1%).</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Elimination</span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>Ixazomib exhibits a multi&#8209;exponential
disposition profile. Based on a population PK analysis, systemic clearance (CL)
was approximately 1.86&nbsp;L/hr with inter&#8209;individual variability of
44%. The terminal half&#8209;life (t<sub>1/2</sub>) of ixazomib was 9.5 days.
Approximately 2&#8209;fold accumulation in AUC was observed with weekly oral
dosing on Day 15.</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excretion</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>After administration of a single oral dose of <sup>14</sup>C&#8209;ixazomib
to 5 patients with advanced cancer, 62% of the administered radioactivity was
excreted in urine and 22% in the faeces. Unchanged ixazomib accounted for
&lt;&nbsp;3.5% of the administered dose recovered in urine.</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><a name="_Toc360524860"><u><span lang=EN-GB
style='font-size:11.0pt;font-weight:normal'>Special populations</span></u></a></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Hepatic impairment</span></u></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The PK of ixazomib
is similar in patients with normal hepatic function and in patients with mild
hepatic impairment (total bilirubin &#8804;&nbsp;ULN and AST &gt;&nbsp;ULN or
total bilirubin &gt;&nbsp;1&#8209;1.5&nbsp;x&nbsp;ULN and any AST) based on the
results of a population PK analysis. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal;font-style:normal'>The PK of ixazomib was
characterized in patients with normal hepatic function at 4&nbsp;mg (N=12), moderate
hepatic impairment at 2.3&nbsp;mg (total bilirubin &gt;&nbsp;1.5&#8209;3&nbsp;x&nbsp;ULN,
N=13) or severe hepatic impairment at 1.5&nbsp;mg (total bilirubin
&gt;&nbsp;3&nbsp;x&nbsp;ULN, N=18). Unbound dose&#8209;normalized AUC was 27%</span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-weight:normal;font-style:normal'>higher in
patients with moderate or severe hepatic impairment as compared to patients
with normal hepatic function (see section&nbsp;4.2).</span></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Renal impairment</span></u></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The PK of ixazomib is similar in patients with normal renal function
and in patients with mild or moderate renal impairment (creatinine clearance &#8805;&nbsp;30&nbsp;mL/min)
based on the results of a population PK analysis. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The PK of ixazomib was characterized at a dose of 3&nbsp;mg in
patients with normal renal function (creatinine clearance &#8805;&nbsp;90&nbsp;mL/min,
N=18), severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;mL/min,
N=14), or ESRD requiring dialysis (N=6). Unbound AUC was 38% higher in patients
with severe renal impairment or ESRD requiring dialysis as compared to patients
with normal renal function.&nbsp;Pre&#8209; and post&#8209;dialyzer
concentrations of ixazomib measured during the haemodialysis session were
similar, suggesting that ixazomib is not dialyzable (see section&nbsp;4.2). </span></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Age, gender, race</span></u></p>

<p class=CCDSMinorSubheading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There was no
clinically meaningful effect of age (23&#8209;91 years), sex, body surface area
(1.2&#8209;2.7&nbsp;m<sup>2</sup>), or race on the clearance of ixazomib based
on the results of a population PK analysis. The mean AUC was 35% higher in
Asian patients; however, there was overlap in the AUC of ixazomib across White
and Asian patients.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Mutagenicity</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib was not
mutagenic in a bacterial reverse mutation assay (Ames assay) or clastogenic in
a bone marrow micronucleus assay in mice. Ixazomib was positive in an <i>in&nbsp;vitro</i>
clastogenicity test in human peripheral blood lymphocytes. However, ixazomib
was negative in an <i>in&nbsp;vivo</i> comet assay in mice, in which percent
tail DNA was assessed in the stomach and liver. Therefore, the weight of
evidence indicates that ixazomib is not considered to present a genotoxic risk.
</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Reproductive and embryo&#8209;foetal development</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Ixazomib caused embryo&#8209;foetal
toxicity in pregnant rats and rabbits only at maternally toxic doses and at
exposures that were slightly higher than those observed in patients receiving
the recommended dose. <span lang=EN-GB>Studies of fertility and early embryonic
development and pre&#8209; and post&#8209;natal toxicology were not conducted
with ixazomib, but evaluation of reproductive tissues was conducted in the
general toxicity studies. There were no effects due to ixazomib treatment on
male or female reproductive organs in studies up to 6&#8209;months duration in
rats and up to 9&#8209;months duration in dogs.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Animal toxicology and/or pharmacology</span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal'><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>In multi&#8209;cycle repeated&#8209;dose toxicity
studies conducted in rats and dogs, the principal target organs included the
gastrointestinal tract, lymphoid tissues, and the nervous system. In the 9&#8209;month
study (10&nbsp;cycles) in dogs orally administered with a dosing schedule mimicking
the clinical regimen (28&#8209;day</span><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt;font-weight:normal'>cycle),
microscopic neuronal effects were generally minimal in nature and only observed
at 0.2&nbsp;mg/kg (4&nbsp;mg/m<sup>2</sup>). The majority of target organ
findings demonstrated partial to full recovery following discontinuation of
treatment, with the exception of neuronal findings in the lumbar dorsal root
ganglion and dorsal column. </span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following oral
administration, a tissue distribution study in rats revealed that the brain and
spinal cord were amongst the tissues with the lowest levels, suggesting that the
penetration of ixazomib through the blood&#8209;brain barrier appears to be
limited. However, the relevance to humans is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
safety pharmacology studies both <i>in&nbsp;vitro</i> (on hERG channels) and <i>in&nbsp;vivo</i>
(in telemetered dogs following </span>single oral administration)<span
lang=EN-GB> demonstrated no effects of ixazomib on cardiovascular or
respiratory functions at </span>AUC more than 8&#8209;fold higher than the
clinical value<span lang=EN-GB>.</span></p>

<p class=CCDSMinorHeading1 align=left style='margin-top:0in;text-align:left;
line-height:normal;page-break-after:auto'><u><span lang=EN-GB style='font-size:
11.0pt;font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>NINLARO 2.3&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=IT>Capsule contents</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=IT>Microcrystalline cellulose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=IT>Capsule shell</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Gelatin</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Red iron
oxide (E172)</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Printing ink</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Shellac</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Propylene glycol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Potassium hydroxide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Black iron oxide
(E172)</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>NINLARO 3&nbsp;mg hard capsules</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Capsule contents</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Capsule shell</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Gelatin</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Black iron oxide (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Printing ink</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Shellac</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Propylene glycol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Potassium hydroxide</span></p>

<p class=MsoNormal style='line-height:normal'>Black iron oxide (E172)</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u>NINLARO 4&nbsp;mg
hard capsules</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u>Capsule contents</u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Microcrystalline
cellulose </p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Capsule shell</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gelatin</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal'>Yellow iron oxide (E172)</p>

<p class=MsoNormal style='line-height:normal'>Red iron oxide (E172) </p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u>Printing
ink</u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Shellac</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Propylene
glycol</p>

<p class=MsoNormal style='line-height:normal'>Potassium hydroxide</p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Black iron oxide (E172)</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&nbsp;&deg;C. Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Store
in the original package in order to protect from moisture. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of container </span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>PVC&#8209;Aluminium
/Aluminium blister sealed inside a wallet pack containing one capsule.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Three
single blister wallet packs are packaged in one carton.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="OLE_LINK1"><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ixazomib is
cytotoxic. The capsule should not be removed until just prior to dosing. The capsules
should not be opened or crushed. Direct contact with the capsule contents
should be avoided. In case of capsule breakage, avoid raising dust during clean&#8209;up.
If contact occurs, wash thoroughly with soap and water. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Pharma A/S</span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1>Delta
Park 45</span><span style='border:none windowtext 1.0pt;padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'>Denmark</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/16/1094/001</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/16/1094/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/16/1094/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: 21 November 2016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of Last
Renewal: 20&nbsp;November&nbsp;2020</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>conditions or restrictions with regard to the
safe and effective use of the medicinal product</span></span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIFIC
OBLIGATION TO COMPLETE POST&#8209;AUTHORISATION MEASURES FOR THE CONDITIONAL
MARKETING AUTHORISATION</span></b></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS RESPONSIBLE FOR
BATCH RELEASE</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Ireland
Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grange Castle
Business Park</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dublin 22</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>D22 XR57</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Production Site
Singen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Robert Bosch
Strasse 8</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>78224 Singen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dybendal Alle 10</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2630 Taastrup</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The printed
package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The requirements
for submission of PSURs for this medicinal product are set out in the list of
Union reference dates (EURD list) </span><span lang=EN-GB>provided for under
Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on
the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder (MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>An updated RMP
should be submitted:</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post&#8209;authorisation
measures</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The MAH shall complete, within the stated timeframe, the below
measure:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=629
 style='margin-left:1.2pt;border-collapse:collapse'>
 <tr>
  <td width=547 valign=top style='width:410.15pt;border:solid black 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Description</span></b></p>
  </td>
  <td width=82 valign=top style='width:61.65pt;border:solid black 1.0pt;
  border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=547 valign=top style='width:410.15pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Post&#8209;authorisation efficacy study (PAES) C16010: To
  provide an interim report of overall survival at the time of the 3<sup>rd</sup>
  interim analysis and to provide a final report for the final analysis of OS
  from the phase 3, randomized, double&#8209;blind study C16010 in adult
  patients with relapsed and/or refractory multiple myeloma.</span></p>
  </td>
  <td width=82 valign=top style='width:61.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>June 2021</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleB>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIFIC OBLIGATION TO
COMPLETE POST&#8209;AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING
AUTHORISATION </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This being a
conditional marketing authorisation and pursuant to Article 14a(4) of
Regulation (EC) No&nbsp;726/2004, the MAH shall complete, within the stated
timeframe, the following measures:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=641
 style='margin-left:1.2pt;border-collapse:collapse'>
 <thead>
  <tr>
   <td width=556 valign=top style='width:417.25pt;border:solid black 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Description</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.75pt;border:solid black 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
   style='color:black'>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=556 valign=top style='width:417.25pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>C16014: In order to further investigate the efficacy the
  MAH should conduct a phase 3, randomized, double&#8209;blind, multicenter
  study comparing ixazomib plus lenalidomide and dexamethasone versus placebo
  plus lenalidomide and dexamethasone in adult patients with newly diagnosed
  multiple myeloma not eligible for stem cell transplantation (SCT) and provide
  the final report for primary endpoint PFS.</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>December 2020</span></p>
  </td>
 </tr>
 <tr>
  <td width=556 valign=top style='width:417.25pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>C16019: In order to further investigate the efficacy the
  MAH should provide additional OS/PFS2 data when approximately 200 death
  events have occurred from the Phase 3, randomized, placebo&#8209;controlled,
  double&#8209;blind study of ixazomib in maintenance therapy in patients with
  multiple myeloma following SCT. </span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>December 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width=556 valign=top style='width:417.25pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>NSMM&#8209;5001: The MAH should conduct a global,
  prospective, non&#8209;interventional, observational study in multiple
  myeloma patients and provide a report with the final analysis when at least
  110 PFS events are expected to have occurred in subjects prospectively
  exposed to ixazomib.</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>July 2022</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON CONTAINING WALLET UNIT PACKS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 2.3&nbsp;mg
hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each hard capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib
citrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 packs of 1
hard capsule.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&ordm;C. Do not freeze. </span></p>

<p class=Default><span style='font-size:11.0pt'>Store in the original package
in order to protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1>Delta
Park 45</span><span style='border:none windowtext 1.0pt;padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'>Denmark</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>EU/1/16/1094/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 2.3&nbsp;mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON CONTAINING WALLET UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 2.3 mg hard
capsules </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each hard capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib
citrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 hard capsule.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&ordm;C. Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal'>Store in the original package in
order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1><span
lang=EN-GB>Delta Park 45</span></span><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>EU/1/16/1094/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 2.3 mg </span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>WALLET</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 2.3 mg hard
capsules </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Hard capsule </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not crush, open or chew the capsules. Take each NINLARO capsule
whole with water at the same time each week, at least one hour before or no
sooner than two hours after any food.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The capsule should not be removed until just prior to dosing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Pharma A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER FOR WALLET</span></b></p>

</div>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 2.3 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON CONTAINING WALLET UNIT PACKS </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 3 mg hard
capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each hard capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib
citrate) </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Hard capsule</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 packs of 1
hard capsule.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&ordm;C. Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal'>Store in the original package in
order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1><span
lang=EN-GB>Delta Park 45</span></span><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>EU/1/16/1094/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 3 mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON CONTAINING WALLET UNIT </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 3 mg hard
capsules </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each hard capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib
citrate) </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 hard capsule. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store above
30&ordm;C. Do not freeze. </span></p>

<p class=Default><span style='font-size:11.0pt'>Store in the original package
in order to protect from moisture.</span></p>

<p class=Default><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1><span
lang=EN-GB>Delta Park 45</span></span><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>EU/1/16/1094/002</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 3 mg </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>WALLET </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 3 mg hard
capsules </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Hard capsule </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not crush, open or chew the capsules. Take each NINLARO capsule
whole with water at the same time each week, at least one hour before or no
sooner than two hours after any food.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The capsule should not be removed until just prior to dosing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Pharma A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER FOR WALLET</span></b></p>

</div>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO 3 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON CONTAINING WALLET UNIT PACKS </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 4 mg hard
capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each hard capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib
citrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 packs of 1
hard capsule.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&ordm;C. Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal'>Store in the original package in
order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1><span
lang=EN-GB>Delta Park 45</span></span><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>EU/1/16/1094/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 4 mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON CONTAINING WALLET UNIT </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 4 mg hard
capsules </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each hard capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib
citrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 hard capsule. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Do not store above 30&ordm;C. Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Store in
the original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1><span
lang=EN-GB>Delta Park 45</span></span><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>EU/1/16/1094/003</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 4 mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>WALLET </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 4 mg hard
capsules </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Hard capsule </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 hard capsule</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not crush, open or chew the capsules. Take each NINLARO capsule
whole with water at the same time each week, at least one hour before or no
sooner than two hours after any food.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The capsule should not be removed until just prior to dosing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Pharma A/S </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-before:always'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER FOR WALLET</span></b></p>

</div>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>NINLARO 4 mg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ixazomib</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-before:always'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-before:always'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>NINLARO 2.3&nbsp;mg hard capsules</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>NINLARO 3&nbsp;mg hard capsules</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>NINLARO 4&nbsp;mg hard capsules</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>ixazomib</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=22 height=18 id="Immagine 3"
src="Ninlaro%20II-25%20EN%20PI%20clea_files/image001.gif" alt="BT_1000x858px"></span><span
lang=EN-GB>This medicine is subject to additional monitoring. This will allow
quick identification of new safety information. You can help by reporting any
side effects you may get. See the end of section&nbsp;4 for how to report side
effects.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor,
pharmacist or nurse. This includes any possible side effects not listed in this
leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp; What
NINLARO is and what it is used for</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp; What
you need to know before you take NINLARO</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp; How
to take NINLARO</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp; How
to store NINLARO</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What NINLARO is and what it
is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What NINLARO is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO is a
cancer medicine that contains ixazomib, a &#8216;proteasome inhibitor&#8217;.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO is used
to treat a cancer of the bone marrow called multiple myeloma. Its active
substance ixazomib works by blocking the action of proteasomes. These are
structures inside the cell that digest proteins and are important for cell
survival. Because myeloma cells produce a lot of proteins, blocking the action
of proteasomes can kill the cancerous cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What NINLARO is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO is used
to treat adults with multiple myeloma.</span><span lang=EN-GB> NINLARO will be
given to you together with lenalidomide and dexamethasone, which are other
medicines used to treat multiple myeloma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>What multiple myeloma is </span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Multiple
myeloma is a cancer of the blood</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> which affects a type of cell, called the plasma cell</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>. A plasma cell is a blood
cell that normally produces proteins to fight infections. People with multiple
myeloma have cancerous plasma cells, also called </span><span lang=EN-GB
style='font-size:11.0pt'><a href="javascript:void(0);"
title="(my-uh-LOW-muh) Cancerous plasma cells."><span style='color:windowtext;
text-decoration:none'>myeloma cells</span></a></span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>, which can damage the bones. Protein
produced by myeloma cells can damage the kidneys. Treatment for multiple
myeloma involves killing myeloma cells and reducing the symptoms of the
disease. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take NINLARO</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take NINLARO</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are
allergic to ixazomib or to any of the other any of the other ingredients of
this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
uncertain whether the condition above applies to you, talk to your doctor,
pharmacist or nurse before taking NINLARO.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before taking or during
treatment with NINLARO if:</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have a history of bleeding</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have persistent nausea, vomiting or diarrhoea</span></p>

<p class=MsoListParagraph style='margin:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have a history of nerve problems, to include tingling and numbness</span></p>

<p class=MsoListParagraph style='margin:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have a history of swelling</span></p>

<p class=MsoListParagraph style='margin:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have a persistent rash</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have or have had liver or kidney problems as
your dose may have to be adjusted</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.5in;
line-height:normal;text-autospace:none'><span style='font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif;color:black'>you
have or have had damage to the smallest blood vessels known as thrombotic
microangiopathy or thrombotic thrombocytopenic purpura. Tell your doctor if you
develop fatigue, fever, bruising, bleeding, decreased urination, swelling,
confusion, vision loss, and seizures.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
examine you and you will be monitored closely during treatment. Before starting
NINLARO and during treatment, you will have blood tests to check that you have
enough blood cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO is not
recommended for use in children and adolescents aged under 18&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and NINLARO</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tell
your doctor, pharmacist or nurse if you are taking, have recently taken or
might take any other medicines. This includes any medicines obtained without a
prescription, such as vitamins or herbal remedies. This is because other
medicines can affect the way NINLARO works. In particular, tell your doctor,
pharmacist or nurse if you are taking any of the following medicines:
carbamazepine, phenytoin, rifampicin and St. John&#8217;s wort (<i>Hypericum </i><i>perforatum</i>).
These medicines should be avoided as they may reduce the effectiveness of
NINLARO.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO is not
recommended during pregnancy as it may harm your unborn baby. Breast&#8209;feeding
should be stopped when taking NINLARO.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Avoid becoming
pregnant or breast&#8209;feeding while being treated with NINLARO. If you are
pregnant or breast&#8209;feeding, think you may be pregnant or are planning to
have a baby, ask your doctor or pharmacist for advice before taking this
medicine. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are a woman of childbearing potential or a man who can father
a child, you </span><span lang=EN-GB>must use effective contraception during
and for 90&nbsp;days after treatment. </span><span lang=EN-GB>Women using
hormonal contraceptives should additionally use a barrier method of
contraception. </span><span lang=EN-GB>Tell doctor right away if you or your
partner becomes pregnant while receiving NINLARO.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>As NINLARO is given in combination with lenalidomide, </span><span
lang=EN-GB>you should adhere to the pregnancy prevention programme of
lenalidomide</span><span lang=EN-GB> because lenalidomide can be harmful to the
unborn child.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>See the package leaflets for lenalidomide and dexamethasone for additional
information on pregnancy and breast&#8209;feeding</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO may
affect your ability to drive or use machines. You may feel tired and dizzy while
taking NINLARO. Do not drive or operate machines if you have these side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take NINLARO</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO must be
prescribed to you by a doctor with experience of treating multiple myeloma.
Always take this medicine exactly as your doctor or pharmacist has told you. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO</span><span
lang=EN-GB> is used with lenalidomide (a medicine which affects how your immune
system works) and dexamethasone (an anti&#8209;inflammatory medicine).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NINLARO,
lenalidomide and dexamethasone are taken in 4&#8209;week treatment cycles. NINLARO
is taken once a week (on the same day of the week) for the first 3&nbsp;weeks
of this cycle. The recommended dose is one 4&nbsp;mg capsule taken by mouth.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of lenalidomide is 25&nbsp;mg taken every day
for the first 3&nbsp;weeks of the cycle. The recommended dose of dexamethasone
is 40&nbsp;mg taken once a week on the same day for all 4&nbsp;weeks of the
cycle. </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 align=left
 style='border-collapse:collapse;border:none;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr>
  <td width=621 colspan=9 valign=top style='width:466.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Dosing schedule: NINLARO taken with lenalidomide
  and dexamethasone</span></b></p>
  <p class=MsoNormal style='margin-left:.5in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-family:Webdings'>a</span><span
  lang=EN-GB>Take medicine</span></p>
  </td>
 </tr>
 <tr>
  <td width=621 colspan=9 valign=top style='width:466.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>28&#8209;day cycle (a 4&#8209;week cycle)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 1</span></b></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 2</span></b></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 3</span></b></p>
  </td>
  <td width=123 colspan=2 valign=top style='width:92.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Week 4</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 valign=top style='width:40.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 1</span></p>
  </td>
  <td width=69 valign=top style='width:51.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>2 to 7</span></p>
  </td>
  <td width=54 valign=top style='width:40.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 8</span></p>
  </td>
  <td width=69 valign=top style='width:51.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>9 to 14</span></p>
  </td>
  <td width=54 valign=top style='width:40.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 15</span></p>
  </td>
  <td width=69 valign=top style='width:51.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>16 to 21</span></p>
  </td>
  <td width=54 valign=top style='width:40.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Day 22</span></p>
  </td>
  <td width=69 valign=top style='width:51.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Days 23 to 28</span></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>NINLARO</span></p>
  </td>
  <td width=54 style='width:40.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=69 style='width:51.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;background:#BFBFBF;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Lenalidomide</span></p>
  </td>
  <td width=54 style='width:40.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span><span lang=EN-GB>Daily</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span><span lang=EN-GB>Daily</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span><span lang=EN-GB>Daily</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=69 style='width:51.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;background:#BFBFBF;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=129 valign=top style='width:96.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Dexamethasone</span></p>
  </td>
  <td width=54 style='width:40.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#BFBFBF;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=54 style='width:40.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:Webdings'>a</span></p>
  </td>
  <td width=69 style='width:51.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;background:#BFBFBF;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>You
should read the Package Leaflets of these other medicines for further
information on their use and effects. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>If
you have liver or kidney problems, your doctor may prescribe NINLARO capsules
containing 3&nbsp;mg. If you have side effects, your doctor may prescribe
NINLARO capsules containing 3&nbsp;mg or 2.3&nbsp;mg. The doctor may also
adjust the doses of the other medicines.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>How and when to take NINLARO </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take NINLARO at least one hour before or at
least two hours after food. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the capsule whole with water. Do not crush,
chew or open the capsule. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not let the contents of the capsule come into
contact with your skin. If the powder accidentally comes into contact with your
skin, wash it off thoroughly with soap and water. If the capsule breaks, clean
up the powder, taking care that it does not cause dust in the air. </span></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>If you take more NINLARO than you
should </span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Accidental overdose
can cause serious side effects.</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>If you take more NINLARO
than you should, talk to a doctor immediately or go to a hospital straight
away. Take the medicine pack with you.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>Duration of the treatment with
NINLARO </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You should
continue treatment until your doctor tells you to stop. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>If you forget to take NINLARO </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>If a dose is missed or delayed, you should take the dose
as long as the next scheduled dose is more than 3 days or 72&nbsp;hours away. </span><span
lang=EN-GB>Do not take a missed dose if it is within 3&nbsp;days or 72&nbsp;hours
of your next scheduled dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you vomit after taking a dose, do not take an extra dose. Take
the next dose, as normal, when it is due. </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>If
you have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor or pharmacist straight away if you
notice any of these following very common serious side effects which may affect
more than 1 in 10 people:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low platelet counts (thrombocytopenia) which may
increase the risk of nose bleeds and you may easily bruise </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea, vomiting and diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>numbness, tingling or burning of the hands or
feet (peripheral neuropathy)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the legs or feet (peripheral oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash that may be itchy and in a few areas
or all over the body </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Additionally, tell a doctor immediately if you notice any of these
following </span></b><b><span lang=EN-GB>rare side effects which may affect up
to 1 in 1,000 people: </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin rashes such as red to purple bumps
(Sweet&#8217;s syndrome) or rash with skin peeling and mouth sores (Stevens&#8209;Johnson
syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle weakness, loss of feelings of the toes
and feet or loss of leg movement (transverse myelitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in vision, changes in mental status, or
seizures (posterior reversible encephalopathy syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rapid death of cancer cells that may cause
dizziness, decreased urination, confusion, vomiting, nausea, swelling,
shortness of breath, or heart rhythm disturbances (tumour lysis syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rare blood condition resulting from blood clots that
may cause fatigue, fever, bruising, bleeding e.g. nose bleeds, decreased
urination, swelling, confusion, vision loss, and seizures (thrombotic
microangiopathy, thrombotic thrombocytopenic purpura)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Other possible
side effects </span></b></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><span style='font-family:
"Times New Roman",serif'>Tell your doctor or pharmacist if any of the side
effects below become severe. </span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Very common side effects may affect
more than 1 in 10 people:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cold&#8209;like symptoms (upper respiratory
tract infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling tired or weak (fatigue)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lowered white blood cells called neutrophils (neutropenia)
that may increase the risk of infection </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>not feeling like eating (decreased appetite)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart rate (arrhythmia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision conditions including blurred vision, dry
eye and pink eye (conjunctivitis)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Common side effects may affect up to 1 in 10 people:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reactivation of the chicken pox virus (shingles)
that can cause a skin rash and pain (herpes zoster)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lowered blood pressure (hypotension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shortness of breath or persistent coughing or
wheezing (heart failure)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>yellow discoloration of eyes and skin (jaundice which
could be a symptom of liver  impairment)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low levels of potassium in the blood
(hypokalaemia)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor, pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:silver'>the national reporting
system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix&nbsp;V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
NINLARO</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the blister, wallet and
carton after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Do
not store above 30&nbsp;&deg;C. Do not freeze. </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Store
in the original package in order to protect from moisture.</span></p>

<p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Do
not remove the capsule until you need to take a dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use this
medicine if you notice any damage or signs of tampering to medicine packaging.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What NINLARO contains </span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>NINLARO
2.3&nbsp;mg hard capsule: </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The active substance is
ixazomib. Each capsule contains 2.3&nbsp;mg of ixazomib (as 3.3&nbsp;mg of
ixazomib citrate).</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The other ingredients are:</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>In the capsule: microcrystalline
cellulose, magnesium stearate and talc.</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The capsule shell contains: gelatin, titanium
dioxide (E171) and red iron oxide (E172) </span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The printing ink contains: shellac, propylene
glycol, potassium hydroxide, and black iron  oxide (E172).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>NINLARO 3&nbsp;mg hard capsule: </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The active substance is
ixazomib. Each capsule contains 3&nbsp;mg of ixazomib (as 4.3&nbsp;mg of
ixazomib citrate). </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The other ingredients are:</span></p>

<p class=Default style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>In the capsule: microcrystalline
cellulose, magnesium stearate and talc.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The capsule shell contains: gelatin, titanium
dioxide (E171) and black iron oxide (E172) </span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The printing ink contains: shellac, propylene
glycol, potassium hydroxide, and black iron oxide (E172).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>NINLARO 4&nbsp;mg hard capsule: </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The active substance is
ixazomib. Each capsule contains 4&nbsp;mg of ixazomib (as 5.7&nbsp;mg of
ixazomib citrate). </span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The other ingredients are</span></p>

<p class=Default style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>In the capsule: microcrystalline
cellulose, magnesium stearate and talc.</span></p>

<p class=Default style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The capsule shell
contains: gelatin, titanium dioxide (E171), yellow iron oxide (E172) and red
iron oxide (E172) </span></p>

<p class=Default style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The printing ink
contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide
(E172).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What NINLARO looks like and contents of the pack</span></b></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>NINLARO 2.3&nbsp;mg hard capsule: Light
pink, size 4, marked &#8220;Takeda&#8221; on the cap and &#8220;2.3&nbsp;mg&#8221;
on the body with black ink.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>NINLARO
3&nbsp;mg hard capsule:</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Light
grey, size 4, marked &#8220;Takeda&#8221; on the cap and
&#8220;3&nbsp;mg&#8221; on the body with black ink.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>NINLARO
4&nbsp;mg hard capsule:</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Light
orange, size 3, marked &#8220;Takeda&#8221; on the cap and
&#8220;4&nbsp;mg&#8221; on the body with black ink.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each pack
contains 3&nbsp;hard capsules (three single cartons, each containing a blister
sealed inside a wallet. Each blister contains one capsule).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Pharma
A/S</span></p>

<p class=MsoNormal style='line-height:normal'><span class=readonlyfield1><span
lang=EN-GB>Delta Park 45</span></span><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'><br>
<span class=readonlyfield1>2665 Vallensbaek Strand</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Ireland
Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grange Castle
Business Park</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dublin 22</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>D22 XR57</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Takeda Pharma A/S</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Dybendal Alle 10</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2630 Taastrup</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Denmark</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Takeda GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
silver'>Takeda (Werk Singen)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
silver'>Robert Bosch Stra&szlig;e 8</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>78224 Singen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='height:67.3pt'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:67.3pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Takeda
  Belgium </span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel/T&eacute;l:
  +32 2 464 06 11 </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>takeda-belgium@takeda.com
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:67.3pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=FI>Lietuva</span></b></p>
  <p class=Default><span lang=FI style='font-size:11.0pt;color:windowtext'>Takeda,
  UAB </span></p>
  <p class=Default><span lang=FI style='font-size:11.0pt;color:windowtext'>Tel:
  +370 521 09 070 </span></p>
  <p class=Default><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#1058;&#1072;&#1082;&#1077;&#1076;&#1072;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103; </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#1058;&#1077;&#1083;.:
  + 359 2 958 27 36</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Takeda
  Belgium </span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel/T&eacute;l:
  +32 2 464 06 11 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>takeda-belgium@takeda.com
  </span></p>
  </td>
 </tr>
 <tr style='height:67.75pt'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:67.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#268;esk&aacute;
  republika</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Pharmaceuticals </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Czech
  Republic s.r.o. </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  + 420 234 722 722 </span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:67.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Pharma Kft. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +361
  2707030 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Danmark</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Pharma A/S </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tlf:
  +45 46 77 11 11 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FI>Malta</span></b></p>
  <p class=Default><span lang=FI style='font-size:11.0pt;color:windowtext'>Takeda
  Italia S.p.A. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +39 06
  502601 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Takeda
  GmbH </span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Tel:
  +49 (0) 800 825 3325</span></p>
  <p class=Default><span lang=DE style='font-size:11.0pt'>medinfoEMEA@takeda.com</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Nederland</span></b></p>
  <p class=Default><span lang=SV style='font-size:11.0pt;color:windowtext'>Takeda
  Nederland bv </span></p>
  <p class=Default><span lang=SV style='font-size:11.0pt;color:windowtext'>Tel:
  +31 23 56 68 777 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>nl.medical.info@takeda.com
  </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=PT-BR>Eesti</span></b></p>
  <p class=Default style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;color:windowtext'>Takeda Pharma AS </span></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Tel:
  +372 6177 669 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-NYN>Norge</span></b></p>
  <p class=Default><span lang=NO-NYN style='font-size:11.0pt;color:windowtext'>Takeda
  AS </span></p>
  <p class=Default><span lang=NO-NYN style='font-size:11.0pt;color:windowtext'>Tlf:
  +47 6676 3030 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>infonorge@takeda.com
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=Default><span lang=NO-NYN style='font-size:11.0pt;color:windowtext'>TAKEDA
  </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#917;&#923;&#923;&#913;&#931;</span><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'> </span><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#913;</span><span
  lang=NO-NYN style='font-size:11.0pt;color:windowtext'>.</span><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#917;</span><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'> </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>T&#951;&#955;</span><span
  lang=NO-NYN style='font-size:11.0pt;color:windowtext'>: +30 210 6387800</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>gr.info@takeda.com
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&Ouml;sterreich</span></b></p>
  <p class=Default><span lang=DE style='font-size:11.0pt;color:windowtext'>Takeda
  Pharma Ges.m.b.H. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +43 (0)
  800-20 80 50 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=Default><span lang=ES style='font-size:11.0pt;color:windowtext'>Takeda
  Farmac&eacute;utica Espa&ntilde;a S.A </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +34 917 90 42 22</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>spain@takeda.com</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PL>Polska</span></b></p>
  <p class=Default><span lang=PL style='font-size:11.0pt;color:windowtext'>Takeda
  Pharma sp. z o.o</span></p>
  <p class=Default><span lang=PL style='font-size:11.0pt'>Tel.: + 48 22 608 13
  00 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=Default><span lang=FR style='font-size:11.0pt;color:windowtext'>Takeda
  France SAS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l:</span><span
  lang=FR> </span><span lang=FR>+ 33 1 40 67 33 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>medinfoEMEA@takeda.com</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=Default><span lang=PT-BR style='font-size:11.0pt;color:windowtext'>Takeda
  Farmac&ecirc;uticos Portugal, Lda. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 351 21
  120 1457 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Pharmaceuticals Croatia d.o.o. </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +385 1 377 88 96 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Products Ireland Limited </span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tel:
  +353 (0) 1 6420021 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Pharmaceuticals SRL </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +40 21
  335 03 91 </span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-NYN>Slovenija</span></b></p>
  <p class=Default><span lang=NO-NYN style='font-size:11.0pt;color:windowtext'>Takeda
  GmbH Podru&#382;nica Slovenija </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>Tel.+ 386 (0)
  59 082 480 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vistor hf. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>S&iacute;mi</span><span
  lang=EN-GB>: +354 535 7000 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>vistor@vistor.is
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Takeda
  Pharmaceuticals Slovakia s.r.o. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +421 (2)
  20 602 600 </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Italia</span></b></p>
  <p class=Default><span lang=IT style='font-size:11.0pt;color:windowtext'>Takeda
  Italia S.p.A. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +39 06
  502601 </span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=Default><span lang=SV style='font-size:11.0pt;color:windowtext'>Takeda
  Oy</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Puh/Tel:</span><span
  lang=SV style='font-size:11.0pt;color:windowtext'> +358 20 746 5000 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=Default><span lang=ES-TRAD style='font-size:11.0pt'>A. Potamitis Medicare
  Ltd</span></p>
  <p class=Default><span lang=ES-TRAD style='font-size:11.0pt;color:windowtext'>T</span><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>&#951;&#955;</span><span
  lang=ES-TRAD style='font-size:11.0pt;color:windowtext'>: </span><span
  lang=ES-TRAD style='font-size:11.0pt'>+357 22583333</span></p>
  <p class=Default><span lang=ES style='font-size:11.0pt'>info@potamitismedicare.com</span><span
  lang=ES style='font-size:11.0pt;color:windowtext'> </span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=Default><span lang=SV style='font-size:11.0pt;color:windowtext'>Takeda
  Pharma AB </span></p>
  <p class=Default><span lang=SV style='font-size:11.0pt;color:windowtext'>Tel:
  +46 8 731 28 00 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>infosweden@takeda.com
  </span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=IT>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=IT>Latvija</span></b></p>
  <p class=Default style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;color:windowtext'>Takeda Latvia SIA </span></p>
  <p class=Default style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;color:windowtext'>Tel: +371 67840082 </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=IT>&nbsp;</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>United Kingdom</span></b></p>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Takeda UK Ltd </span></p>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Tel: +44 (0)1628 537 900 </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.<a
name="_GoBack"></a></span></p>

</div>

</body>

</html>
